Recovery
BPC-157
per administration
Only animal or lab studies exist — no human study has set an amount.
Quick start
BPC-157 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 200–500 mcg per administration
- How often
- Every day
- Where
- Commonly subcutaneous Sites and rotation
- Timing
- No strong time-of-day pattern; often split into two doses and placed near the area being worked on in community reports.
- What people report
- Discussed as days to a couple of weeks for soft-tissue and gut-related contexts in reports.
- Time to steady level
- ~20 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
- Cycle length
- 4–6 weeks
- Break between
- 2–4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C62H98N16O22
- Mol. weight
- 1,419.5 Da
- CAS
- 137525-51-0
- PubChem CID
- 9941957
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for BPC-157 describe 200–500 mcg per administration. Descriptive only, not a recommendation.
Poorly characterized; published estimates vary widely.
No human dose-ranging study fixes an injected amount or schedule; the figures in circulation come from animal repair models and community reports, so no schedule table is shown.
What it can be combined with
How BPC-157 is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- KLOWKLOW already contains BPC-157, so adding standalone BPC-157 doubles that component — account for the blend's share first.Use caution
- GHK-CuDifferent mechanisms; no reported interaction.Commonly combined
- SemaglutideDifferent mechanisms; BPC-157 is commonly discussed for gastrointestinal comfort during GLP-1 use, with no adverse interaction reported.Commonly combined
- TB-500A commonly-paired recovery combination; no shared mechanism or reported interaction.Commonly combined
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.02× single dose
- Time to steady state
- 20hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Preclinical injury-model literatureMost BPC-157 evidence is rodent tendon, ligament and gut-repair models; human amounts are community-derived, not established.